Organon & Co. (NYSE:OGN) Shares Purchased by LSV Asset Management

LSV Asset Management raised its holdings in Organon & Co. (NYSE:OGN - Free Report) by 10.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,349,579 shares of the company's stock after purchasing an additional 317,727 shares during the period. LSV Asset Management owned about 1.31% of Organon & Co. worth $48,301,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nordea Investment Management AB lifted its holdings in Organon & Co. by 2,016.0% during the fourth quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company's stock valued at $44,648,000 after purchasing an additional 2,980,945 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Organon & Co. by 23.7% during the third quarter. Invesco Ltd. now owns 10,240,630 shares of the company's stock valued at $177,777,000 after acquiring an additional 1,963,682 shares during the last quarter. Private Management Group Inc. lifted its position in shares of Organon & Co. by 78.5% in the fourth quarter. Private Management Group Inc. now owns 2,335,238 shares of the company's stock valued at $33,674,000 after acquiring an additional 1,027,276 shares in the last quarter. Sound Income Strategies LLC boosted its stake in shares of Organon & Co. by 140,626.7% in the fourth quarter. Sound Income Strategies LLC now owns 489,729 shares of the company's stock worth $7,062,000 after acquiring an additional 489,381 shares during the last quarter. Finally, FMR LLC increased its position in shares of Organon & Co. by 28.3% during the third quarter. FMR LLC now owns 2,189,693 shares of the company's stock worth $38,013,000 after purchasing an additional 483,257 shares in the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Piper Sandler raised their price objective on Organon & Co. from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Monday, April 29th. The Goldman Sachs Group raised their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a "neutral" rating in a research note on Friday.

Organon & Co. Trading Up 0.6 %

NYSE:OGN traded up $0.11 during trading hours on Friday, hitting $19.61. The company had a trading volume of 3,217,591 shares, compared to its average volume of 2,337,626. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.08. The company has a market cap of $5.04 billion, a P/E ratio of 4.79, a P/E/G ratio of 0.92 and a beta of 0.81. The company has a 50-day moving average of $18.19 and a 200 day moving average of $15.76.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.14. Organon & Co. had a net margin of 16.50% and a negative return on equity of 259.73%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.55 billion. On average, analysts forecast that Organon & Co. will post 4.1 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Shareholders of record on Monday, May 13th will be given a $0.28 dividend. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a yield of 5.71%. Organon & Co.'s dividend payout ratio is currently 27.38%.

Insider Activity

In other Organon & Co. news, insider Kirke Weaver acquired 2,720 shares of the business's stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now owns 15,181 shares of the company's stock, valued at $278,723.16. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.17% of the company's stock.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.